secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001790340-26-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering: FY2025 net loss $56M, cash $217M, 64% OS at 12 months in pancreatic cancer
--------------------------------------------------------------------------------

- Net loss for FY2025 was $56.0M ($1.27/share), down from $61.0M ($2.04/share) in 2024.
- Cash and marketable securities $217.0M as of Dec 31, 2025, with anticipated runway into 2029.
- Phase 2a pancreatic cancer data: 64% OS at 12 months for atebimetinib + mGnP, above standard of care 35%.
- Pivotal Phase 3 MAPKeeper 301 on track to dose first patient mid-2026; FDA and EMA alignment secured.
- Plan to dose first patient in Phase 2 trial of atebimetinib + Libtayo in RAS-mutant NSCLC in 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000040/0001790340-26-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000040/imrx-20260306.htm
  HTML page:      https://secwatch.observer/filing/0001790340-26-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer